“New Drug Discovery, Development & Manufacturing Platforms” was moderated by Kristen Kluska and featured Tom Isett, CEO of iBio, Inc. and Jeff Wolf, CEO of NightHawk Biosciences, Inc.

• iBio highlighted its focus in oncology which is led by IBIO-101, an IL-2 sparing anti-CD25 antibody.

• Nighthawk Biosciences discussed its ecosystem which works across discovery, development, and biomanufacturing.

#Cantorconferenceseries #Oncology #Hematology #Hemeonc #Cantorfitzgerald #Cantorhealthcare